Boston Scientific Co. (NYSE:BSX) is Crystal Rock Capital Management’s 8th Largest Position

Crystal Rock Capital Management lessened its holdings in Boston Scientific Co. (NYSE:BSX) by 7.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 85,100 shares of the medical equipment provider’s stock after selling 6,425 shares during the quarter. Boston Scientific makes up about 4.7% of Crystal Rock Capital Management’s holdings, making the stock its 8th largest position. Crystal Rock Capital Management’s holdings in Boston Scientific were worth $7,601,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. MONECO Advisors LLC increased its stake in Boston Scientific by 7.6% in the third quarter. MONECO Advisors LLC now owns 3,861 shares of the medical equipment provider’s stock valued at $324,000 after purchasing an additional 272 shares during the last quarter. Jacobsen Capital Management boosted its holdings in shares of Boston Scientific by 4.9% in the 3rd quarter. Jacobsen Capital Management now owns 2,820 shares of the medical equipment provider’s stock valued at $236,000 after buying an additional 133 shares in the last quarter. Highview Capital Management LLC DE grew its position in shares of Boston Scientific by 17.2% in the 3rd quarter. Highview Capital Management LLC DE now owns 23,068 shares of the medical equipment provider’s stock valued at $1,933,000 after buying an additional 3,388 shares during the last quarter. Adams Diversified Equity Fund Inc. acquired a new stake in Boston Scientific during the 3rd quarter worth $17,908,000. Finally, Golden State Equity Partners lifted its position in Boston Scientific by 1.4% in the third quarter. Golden State Equity Partners now owns 10,614 shares of the medical equipment provider’s stock valued at $889,000 after acquiring an additional 151 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BSX has been the topic of several research reports. Piper Sandler raised their price objective on Boston Scientific from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Canaccord Genuity Group upped their target price on Boston Scientific from $98.00 to $101.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Morgan Stanley lifted their price target on Boston Scientific from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Citigroup increased their price objective on Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a report on Friday, January 10th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $107.39.

Insider Activity

In other news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the sale, the executive vice president now directly owns 29,308 shares in the company, valued at approximately $2,660,580.24. This trade represents a 19.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP John Bradley Sorenson sold 4,119 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the sale, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. This represents a 10.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 144,305 shares of company stock worth $14,954,985 in the last 90 days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Performance

Shares of BSX stock opened at $101.61 on Thursday. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The stock has a 50 day simple moving average of $98.73 and a 200-day simple moving average of $89.95. The company has a market cap of $149.96 billion, a price-to-earnings ratio of 81.29, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a 12-month low of $65.52 and a 12-month high of $107.17.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, equities analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.